Formulary Amendments |
Chapter |
Change |
Reason for change |
02.16 |
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy |
NICE TA913 & NHSE SSC2590 |
04.02.01 |
Addition of benperidol for control of deviant antisocial sexual behaviour |
Formulary merger |
04.09.03 |
Riluzole for the treatment of Motor Neuron Disease with swallowing difficulties where crushing tablets is not appropriate |
NENC Medicines Committee approval |
07.04.05 |
Tadalafil 5mg daily tablets for erectile dysfunction |
NENC Medicines Committee approval |
08.01.05 |
Atezolizumab - new subcutaneous formulation added |
NHSE SSC2560 |
08.01.05 |
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable |
NICE TA917 & NHSE SSC 2565 |
08.01.05 |
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments |
NICE TA927 & NHSE SSC 2574 |
08.01.05 |
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (NICE TA809) |
NHSE SSC2568 |
08.01.05 |
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, falloian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (NICE TA908) |
NHSE SSC2566 |
08.01.05 |
Pembrolizumab for previously treated endometrial, bilary, colorectal, gastric and small intestine cancer with high microsetellite instability or mismatch repair deficiency |
NICE TA914 & NHSE SSC 2593 |
08.01.05 |
Pembrolizumab with lenvatinib for previously treated advance or recurrent endometrial cancer (NICE TA904) |
NHSE SSC 2561 |
08.01.05 |
Ruxolitinib for treating polycythaemia vera |
NICE TA921 & NHSE SSC 2564 |
08.01.05 |
Crizanlizumab removed from the formulary |
NHSE SSC2609 & MHRA Drug Safety Recall |
08.03.04.02 |
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (NICE TA903) |
NHSE SSC 2562 |
09.02.01.02 |
Sodium Chloride 5mmol/ml oral solution in accordance with NPPG/RCPH Position Statement |
NENC Medicines Committee approval |
09.06.04 |
Adcal-D3 effervescent tablets and Cacit D3 sachets following discontinuation of Calfovit D3 effervescent granules. Merged all preparations into one calcium carbonate/colecalciferol entry |
NENC Medicines Committee approval |
09.08.01 |
Cipaglucosidase alfa (CIPA) plus miglustat for treating late-onset Pompe disease in adults. Information only |
NICE TA912 & NHSE SSC 2557 |
10.01.03 |
Bimekizumab for treating axial spondyloarthritis |
NICE TA918 |
10.01.03 |
Tofacitinib for treating active ankylosing spondylitis |
NICE TA920 |
10.02.02 |
Quinine sulphate for nocturnal leg cramps |
NENC Medicines Committee approval |
12.01.01 |
Ciprofloxacin ear drops 0.2% for the treatment of otitis externa. Changed fron Green+ to Green |
NENC Medicines Committee approval |
12.01.02 |
Otitis media with effusion in under 12s - link added |
NICE NG233 |
13.02.01 |
AquaGel (oil free) lubricating jelly for the relief of dryness of the nose, lips and face when a patient is using oxygen via nasal prongs CPAP masks etc |
NENC Medicines Committee approval |
13.08.01 |
Anthelios Sunscreen Lotion following the discontinuation of Sunsense |
NENC Medicines Committee approval |
15.01.04.01 |
Midazolam 10mg/2ml injection in palliative care. Changed from Green+ to Green |
NENC Medicines Committee approval |